What is Retatrutide 40mg?
Retatrutide is the most potent weight-reduction compound currently in clinical development — a triple GLP-1R/GIPR/GCGR agonist producing 24.2% mean body weight reduction at 48 weeks in Phase 2 trials (the highest of any pharmacological compound in human clinical research). The 40mg/vial format provides a high-dose configuration suited for intensive research protocols. GLP-1R provides appetite suppression; GIPR enhances insulin secretion and adipocyte effects; GCGR adds direct hepatic fat mobilisation, brown adipose thermogenesis, and energy expenditure independently of food intake.
Research Applications
High-Dose Triple Agonist Research
40mg/vial provides a concentrated format for research requiring sustained high-dose retatrutide exposure — extended protocols, dose-response ceiling studies.
Triple Agonist Mechanism Research
GLP-1R + GIPR + GCGR simultaneous activation — research into which receptor combination drives superior outcomes vs dual or single agonist comparators.
Obesity Pharmacology — Phase 3 Range
40mg format aligns with upper Phase 2 dosing ranges — enables translational research at clinically relevant concentrations.
Quick Specs
| Product | Retatrutide 40mg × 10 Vials (400mg total) |
| Mechanism | Triple GLP-1R / GIPR / GCGR agonist |
| Phase 2 Data | 24.2% mean weight reduction, 48 weeks |
| Format | Lyophilised powder, 10-vial kit |
| Purity | ≥99% HPLC, MS confirmed |
| Storage | −20°C lyophilised; 4°C reconstituted |
